Evidence map›Paper›PMID 41871918›Full record

ArticleRMD open2026

Increased synovial and entheseal fibroblast activation detected by

Giulia Corte, Armin Atzinger, Rita Noversa de Sousa, Melek Yalcin Mutlu, Alp Temiz, Sara Bayat, Maria Gabriella Raimondo, Andreas Ramming, Michael Sticherling, Christian Schmidkonz and 4 more

Abstract read
In one paragraph

Article in RMD open, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Giulia CorteDepartment of Internal Medicine 3, Friedrich-Alexander University (FAU) Erlangen-Nürnberg and Universitätsklinikum Erlangen, Erlangen, Germany giulia.corte@uk-erlangen.de.ORCID 0009-0007-2218-6503
Armin AtzingerDepartment of Nuclear Medicine, Friedrich-Alexander University (FAU) Erlangen-Nürnberg and Universitätsklinikum Erlangen, Erlangen, Germany.
Rita Noversa de SousaDepartment of Internal Medicine 3, Friedrich-Alexander University (FAU) Erlangen-Nürnberg and Universitätsklinikum Erlangen, Erlangen, Germany.
Melek Yalcin MutluDepartment of Internal Medicine 3, Friedrich-Alexander University (FAU) Erlangen-Nürnberg and Universitätsklinikum Erlangen, Erlangen, Germany.
Alp TemizDepartment of Internal Medicine 3, Friedrich-Alexander University (FAU) Erlangen-Nürnberg and Universitätsklinikum Erlangen, Erlangen, Germany.ORCID 0000-0003-0804-3198
Sara BayatDepartment of Internal Medicine 3, Friedrich-Alexander University (FAU) Erlangen-Nürnberg and Universitätsklinikum Erlangen, Erlangen, Germany.ORCID 0000-0002-2799-184X
Maria Gabriella RaimondoDepartment of Internal Medicine 3, Friedrich-Alexander University (FAU) Erlangen-Nürnberg and Universitätsklinikum Erlangen, Erlangen, Germany.
Andreas RammingDepartment of Internal Medicine 3, Friedrich-Alexander University (FAU) Erlangen-Nürnberg and Universitätsklinikum Erlangen, Erlangen, Germany.
Michael SticherlingDeutsches Zentrum Immuntherapie (DZI), Friedrich-Alexander University (FAU) Erlangen-Nürnberg and Universitätsklinikum Erlangen, Erlangen, Germany.
Christian SchmidkonzDepartment of Nuclear Medicine, Friedrich-Alexander University (FAU) Erlangen-Nürnberg and Universitätsklinikum Erlangen, Erlangen, Germany.
Torsten KuwertDepartment of Nuclear Medicine, Friedrich-Alexander University (FAU) Erlangen-Nürnberg and Universitätsklinikum Erlangen, Erlangen, Germany.
Georg SchettDepartment of Internal Medicine 3, Friedrich-Alexander University (FAU) Erlangen-Nürnberg and Universitätsklinikum Erlangen, Erlangen, Germany.
Koray TascilarDepartment of Internal Medicine 3, Friedrich-Alexander University (FAU) Erlangen-Nürnberg and Universitätsklinikum Erlangen, Erlangen, Germany.ORCID 0000-0002-8109-826X
Filippo FagniDepartment of Internal Medicine 3, Friedrich-Alexander University (FAU) Erlangen-Nürnberg and Universitätsklinikum Erlangen, Erlangen, Germany.ORCID 0000-0002-6122-0774

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectivesTo assess the clinical and imaging characteristics associated with fibroblast activation detected by

methodsPsoriasis patients with arthralgia underwent

results45 patients with psoriasis were enrolled, 37 of whom (82%) were FAPI positive. FAPI-positive psoriasis patients had significantly higher body mass index (BMI) (p=0.036) and Disease Activity Score 28-C reactive protein (p=0.033) compared with FAPI-negative patients.

conclusionsIn psoriasis patients with arthralgia,

Indexed as

ArthralgiaArthritis, PsoriaticFibroblastsPositron Emission Tomography Computed TomographyPsoriasisSynovial MembraneAdultBiomarkersDisease ProgressionEndopeptidasesFemaleFibroblast Activation Protein AlphaHumansMaleMiddle AgedQuinolines68Ga-FAPIBiomarkersEndopeptidasesFibroblast Activation Protein AlphaQuinolinesBiomarkersFibroblastsPsoriasisPsoriatic ArthritisRisk Factors

Identifiers

PMID41871918
PMCPMC13034247

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.